Skip to main content
Clinical Trials/NCT00464204
NCT00464204
Completed
Phase 3

Effects of Voluven on Hemodynamics and Tolerability of Enteral Nutrition in Patients With Severe Sepsis

Fresenius Kabi24 sites in 2 countries196 target enrollmentJuly 2007

Overview

Phase
Phase 3
Intervention
6 % Hydroxyethylstarch 130/0.4 = "Voluven®"
Conditions
Sepsis
Sponsor
Fresenius Kabi
Enrollment
196
Locations
24
Primary Endpoint
Amount of Study Drug Required to Achieve Initial Hemodynamic Stabilization
Status
Completed
Last Updated
14 years ago

Overview

Brief Summary

The rapidity and the quality of fluid resuscitation in patients with severe sepsis are important factors for the prevention of secondary multi-organ failure. Vascular filling may also have an impact on tolerability of enteral nutrition. The earliness and quantity of calories provided by enteral nutrition may have an impact on morbidity and mortality. This study will asses the effects of volume expansion on hemodynamics and tolerability of enteral nutrition in patients with severe sepsis. A Data Monitoring Committee will review regularly safety data of the study.

Registry
clinicaltrials.gov
Start Date
July 2007
End Date
December 2010
Last Updated
14 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Severe sepsis
  • Requirement for fluid resuscitation

Exclusion Criteria

  • serum creatinine \> 300µmol/L
  • Chronic renal failure
  • Anuria lasting more than 4 hours
  • Requirement for renal support

Arms & Interventions

Voluven® Arm

Intervention: 6 % Hydroxyethylstarch 130/0.4 = "Voluven®"

0.9 % NaCl

Intervention: 0.9 % NaCl

Outcomes

Primary Outcomes

Amount of Study Drug Required to Achieve Initial Hemodynamic Stabilization

Time Frame: until hemodynamic stabilization (up to 48 hours)

Initial hemodynamic stabilization (HDS) was defined as normalization of mean arterial pressure (MAP) and at least two of the three parameters central venous pressure (CVP), urine output and central venous oxygen saturation and maintaining this normalization over a period of four hours, with no increase in the infusion of vasopressors, or ionotropic therapy and with no more than 1 L of additional study drug administration within these four hours.

Secondary Outcomes

  • Time From Start of Fluid Resuscitation With Study Drug to the Initial Hemodynamic Stabilization(until hemodynamic stabilization (up to 48 hours))
  • Quantity of Study Drug in 4 Days(4 days)
  • Time From Start of Study Drug to Start of Enteral Nutrition in the Subgroup of Patients Who Received Enteral Nutrition(Until start of enteral nutrition (up to 48 hours))
  • Time From Start of Fluid Resuscitation With Study Drug to Start of Enteral Nutrition After Hemodynamic Stabilization(up to 48 hours)
  • Total Amount of Enteral Calories During the First Seven Days of Enteral Nutrition(7 days)
  • Length of Stay in the Intensive Care Unit (ICU)(Until discharge from ICU (up to day 90))
  • Length of Stay in the ICU(Until discharge from ICU (up to Day 90))
  • Length of Stay in the Hospital(Until discharge from hospital (up to day 90))
  • Area Under the Curve (AUC) of Sepsis-related Organ Failure Assessment (SOFA) Score Per Day From Screening to Day 4(From Screening to Day 4)

Study Sites (24)

Loading locations...

Similar Trials